TRV GP III’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

TRV GP III’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,148,780	Closed	-$2.69M	–	6
2022 Q3	$2.69M	Hold	1,148,780	–	–	1.17%	6
2022 Q2	$3.48M	Hold	1,148,780	–	–	1.42%	7
2022 Q1	$7.8M	Hold	1,148,780	–	–	2.12%	7
2021 Q4	$9.59M	Sell	1,148,780 -1,900,000	-62%	-$15.7M	2.4%	7
2021 Q3	$22.7M	Hold	3,048,780	–	–	4.3%	6
2021 Q2	$20.7M	Hold	3,048,780	–	–	3.62%	7
2021 Q1	$31.3M	Hold	3,048,780	–	–	3.96%	6
2020 Q4	$21.3M	Hold	3,048,780	–	–	1.83%	7
2020 Q3	$24.9M	Hold	3,048,780	–	–	2.09%	7
2020 Q2	$21M	Hold	3,048,780	–	–	3.07%	5
2020 Q1	$14.5M	Hold	3,048,780	–	–	3.94%	5
2019 Q4	$26.6M	Hold	3,048,780	–	–	11.75%	3
2019 Q3	$10.2M	Hold	3,048,780	–	–	5.75%	4
2019 Q2	$15.1M	Hold	3,048,780	–	–	6.42%	3
2019 Q1	$18.9M	Hold	3,048,780	–	–	9.26%	3
2018 Q4	$10.3M	Hold	3,048,780	–	–	8.61%	3
2018 Q3	$19.8M	Hold	3,048,780	–	–	8.85%	3
2018 Q2	$23.4M	Hold	3,048,780	–	–	7.78%	3
2018 Q1	$68.1M	Hold	3,048,780	–	–	24.53%	2
2017 Q4	$38.9M	Buy	+3,048,780	New	+$44.8M	13.61%	3

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TRV GP III's JNCE Position: Q4 2022 in Review

TRV GP III sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 1,148,780 shares — an estimated $2.69M sold.

TRV GP III first reported a position in JNCE in Q4 2017 and held it in 20 quarters. The position peaked at $68.1M in Q1 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

TRV GP III reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
TRV GP III sold 1,148,780 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $2.69M.
TRV GP III first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 20 quarters.
TRV GP III's Jounce Therapeutics, Inc. Common Stock position peaked at $68.1M in Q1 2018.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on TRV GP III's 13F filing for Q4 2022, filed 14 Feb 2023.